ReviewCurrent opinion in HIV and AIDS2025
Resist to persist: resistance of the HIV reservoir to immune-mediated clearance.
Review in Current opinion in HIV and AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HIV Nef amplifies mechanical heterogeneity to promote immune evasion.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines recent research on the mechanisms underlying resistance to cytotoxic T lymphocyte (CTL)-mediated killing, commonly referred to as 'CTL-resistance', which contributes in the persistence of the HIV-1 reservoir and represents a major barrier to achieving an HIV-1 cure. RECENT
findingsRecent discoveries have revealed that the viral reservoir in people with HIV (PWH) in long-term antiretroviral (ART) treatment is enriched within cells exhibiting a pro-survival phenotype, reduced antigen presentation capacity, or intrinsic mechanisms that may directly counteract cytotoxic responses, thereby facilitating immune-killing evasion. Among many others, overexpression of the antiapoptotic protein BCL-2, the pro-survival factor BIRC-5/SURVIVIN and its upstream regulator OX40, the histone methyltransferase EZH-2, or a quiescent metabolic profile with reduced reactive oxygen species production have been described as the most notable mechanisms of CTL-resistance. SUMMARY: While several advances in HIV therapeutic vaccines have demonstrated its ability to induce strong polyfunctional CTL responses associated with improved viral control, vaccine-induced responses fail to reduce reservoir levels- which might be partially due to a CTL-resistant HIV reservoir able to evade immune-mediated clearance. Strategies aimed at reversing this CTL-resistance or sensitize the HIV-1 reservoir might improve the efficacy of future immunotherapies aimed at achieving a durable ART-free control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.